50 results about "Phosphagen" patented technology

Sequence-specific oligonucleotides are provided having substantially pure chiral Sp phosphorothioate, chiral Rp phosphorothioate, chiral Sp alkylphosphonate, chiral Rp alkylphosphonate, chiral Sp phosphoamidate, chiral Rp phosphoamidate, chiral Sp phosphotriester, and chiral Rp phosphotriester linkages. The novel oligonucleotides are prepared via a stereospecific SN2 nucleophilic attack of a phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate anion on the 3' position of a xylonucleotide. The reaction proceeds via inversion at the 3' position of the xylo reactant species, resulting in the incorporation of phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate linked ribofuranosyl sugar moieties into the oligonucleotide.

The present invention relates to a biodegradable and thermosensitive poly(organophosphazene) with a functional group, a preparation method thereof, and a use thereof for delivery of bioactive substances. According to the present invention, poly(organophosphazene) is a phosphagen-based polymer showing biodegradability, thermosensitivity, and sol-gel phase transition depending on temperature change, whereby when administered into a living body with bioactive substances such as drugs, the poly(organophosphazene) forms a gel-phase at body temperature to be capable of controlled release of the bioactive substances. Further, the poly(organophosphazene) has functional groups to chemically bind with bioactive substances through an ionic bond, covalent bond, or coordinate covalent bond to be capable of a sustained release of the bioactive substances due to its good binding property. Therefore, the poly(organophosphazene) is useful as a delivery material for bioactive substances.

The invention relates to a method for preparing phosphatidylserine abundant in polyunsaturated fatty acid and belongs to the technical field of bioengineering. The method is characterized by comprising the following steps of: firstly, catalyzing ester exchange reaction between phosphatide and polyunsaturated fatty acid ester by utilizing one or a mixture of phosphatidase A and lipase to generate phosphatide abundant in polyunsaturated fatty acid; and then catalyzing phosphor-transfer esterification reaction between the phosphatide abundant in the polyunsaturated fatty acid and L-serine by utilizing phosphatidase D to generate the phosphatidylserine abundant in the polyunsaturated fatty acid. The method has the advantages of no discharge of waste water, good product quality, no solvent residue, safe process operation, few reaction byproducts, no waste generation, cost reduction, simple production process and easy realization of scale production because of utilizing two enzymes to perform sub-step catalysis and perform reaction in the same reactor, and completing the reaction process in a non-solvent system. Therefore, the invention provides a good and feasible method for preparing the phosphatidylserine abundant in the polyunsaturated fatty acid.

Sequence-specific oligonucleotides are provided having substantially pure chiral Sp phosphorothioate, chiral Rp phosphorothioate, chiral Sp alkylphosphonate, chiral Rp alkylphosphonate, chiral Sp phosphoamidate, chiral Rp phosphoamidate, chiral Sp phosphotriester, and chiral Rp phosphotriester linkages. The novel oligonucleotides are prepared via a stereospecific SN2 nucleophilic attack of a phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate anion on the 3' position of a xylonucleotide. The reaction proceeds via inversion at the 3' position of the xylo reactant species, resulting in the incorporation of phosphodiester, phosphorothioate, phosphoramidate, phosphotriester or alkylphosphonate linked ribofuranosyl sugar moieties into the oligonucleotide.

The invention discloses an active polypeptide capable of promoting osteogenesis and inhibiting osteoclast and application of the active polypeptide. N-terminal serine is phosphorylated on the basis ofPTH1-34, and three repeated sequences of glutamic acid or aspartic acid are introduced at a C terminal; the sequence of the polypeptide is shown in SEQ ID NO:1 or SEQ ID NO:2, and the polypeptide hasosteoinductive activity similar to BMP2 and an osteoclast inhibiting effect similar to parathyroid hormones (PTH). Random coils of the polypeptide can be avoided by bonding the C-terminal repeated sequences of the polypeptide to the surface of a calcium phosphate material or a material with a calcium phosphate coating, no addition of organic reagents is needed, and therefore the activity of the polypeptide is protected effectively; furthermore, slow controlled release can be achieved through cleavage of peptide bonds, and long-term intermittent injection of the PTH1-34 can be avoided, so thatthe injection pain of patients is reduced, and effects of osteoblast promotion and osteoporosis inhibition are achieved; a conventional viewpoint that the PTH1-34 cannot be administered locally is changed.

The invention discloses an organophosphorus pesticide degrading enzyme gene and application thereof. The gene is obtained through site-specific mutagenesis on three amino acid coding loci, the 253rd locus, the 256th locus and the 271st, on the organophosphorus degrading enzyme gene. The nucleotide sequence with mutated organophosphorus pesticide degrading enzyme gene is connected to a pHT43 vector, then the expression vector is transferred into Bacillus subtilis host cells for expression, so as to isolate expression protein with organophosphorus pesticide degrading activity. The organophosphorus pesticide degrading enzyme expressed by mutant gene provided by the invention has obviously improved affinity and sensitivity with a substrate ethyl-parathion, and obviously improved enzyme activity; the invention can be used for degradation and elimination of organic phosphorus pesticide residues in agricultural products and opens up a novel path for the engineering enzymatic degradation of organophosphorus pesticide.

The invention provides a novel phospholipid derived compound shaped like phospholipid-PEG (polyethylene glycol)-folic acid or phospholipid-PEG-rhamnose, and further provides a liposome medicine combination containing the phospholipid derived compound and a preparation method of the liposome medicine combination. The novel phospholipid derived compound can be used for cancer targeting immunotherapy, and cancer cells are killed by complement dependent toxicity immuno-targeting. Rhamnose and folic acid modified phospholipid is used as a raw material to prepare liposome, targeting property is fine, the cancer cells are efficiently killed by making full use of human natural immunity, toxic and side effects are small, and the liposome is suitable for clinical application research and industrial production.

The present invention relates to the field of catalytic hydrogenation and, more particularly, to the use of specific ruthenium catalysts, or pre-catalysts, in hydrogenation processes with molecular H2 for the reduction of ketones, aldehydes and esters or lactones into the corresponding alcohol or diol respectively. Said catalysts are ruthenium complexes comprising a ligand of the type (N-N) type, in which at least one of said amino groups is a secondary or primary amine (i.e. a NH or NH2) and a ligand of the type (P-N) in which N belongs to a tertiary amino group, a N, N, N' trisubstituted carboxiamide (a C(=N)N moiety) or a N-substituted imidoate (a C(=N)O moiety).

The invention discloses a method for preparing intermediates for 25-hydroxyvitamin D2 and 1 alpha, 25-dihydroxyvitamin D2. The structures of the intermediates are compounds 2 and 3 shown as the following formula 1. The preparation method is shown as the following formulas, and comprises the following steps of: treating a phosphorus oxide 9 by using strong base, and performing a Wittig-Hormer reaction with aldehyde 5 or 6. Formula 1.

The invention discloses a phosphorus deficiency specific inducement root-expression promoter and applications thereof. The promoter can be a DNA molecule as the following 1), 2) or 3): (1) the ribonucleotide sequence thereof is a DNA molecule in the 1st-serial in a sequence list; (2) a DNA molecule which can be hybridized with the DNA molecule of the 1st-serial in the sequence list under a strict condition and can drive targeted genes to be expressed specially in root in case of phosphorus deficiency; (3) a DNA molecule which has the homeology with the DNA by more than 90 percent and can drive targeted genes to be expressed specially in root in case of phosphorus deficiency. The promoter of the invention can be applied to the construction of carriers with economic value and the constructed carriers can be used for breeding transgenic plants with economic value.

The invention relates to a method for detecting activation of microencapsulated cells. The detection comprises the steps of sample extraction and phosphagen separation and quantification. The activation of the cell in a representation microcapsule is calculated through energy charge. The invention designs an operation scheme for the phosphagen quantification of microencapsulated cells to such special microcapsule system, which can accurately quantify the phosphagen content in the microencapsulated cells, and avoids the defects in the prior art such as large sample loss during extraction, unstable test, bad repeatability, etc., and the test results can be regarded as the evaluation indexes for the activation of the microencapsulated cells.

The invention discloses a construction approach for bacillus coli of transpolyphosphokinase gene, in which the said method includes gene-clone and carrier-construction; the clone includes extracting master DNA of bacillus coli; designing primers; augmenting ppk gene; restructuring the augmented object gene into clonic carrier pMD18-T and converting bacillus coli DH5 alpha; the construction includes adopting restriction enzymes of BamHI and HindIII bisenzyme to cut pMD18-T plasmid with ppk object gene and idle expression carrier pET-28a(+); directionally connecting the object gene by T4 to the expression carrier pET-28a(+), then converting the DH5 alpha; by the PCR and bisenzyme pressure methods screening and verifying the positive recon; extracting the recombination plasmid Pet28a-PPK and converting the acceptor strain BL21(DE3). The invention is of simple process and the obtained gene has efficient phosphorous removal ability.

The invention provides a recombinant phospholipase D, which is a novel PLD (phospholipase D) screened through an escherichia coli surface display technology, a high throughput screening technology anda DNA gene recombination technology. The amino acid sequence of the recombinant phospholipase D provided by the invention is SEQ ID NO:1. The transesterification vitality of the recombinant phospholipase PLDr34 is improved by 3.24 times, a conversion rate is 80.3%, selectivity is 86.8%, and the recombinant phospholipase D is an ideal catalyst synthesized by PS (phosphatidylserine), DHA-PS and other rare phospholipids.

Nucleotide analogs characterized by the presence of an amidate linked amino acid or an ester linked group which is bonded to the phosphorus atom of phosphonate nucleotide analogs are disclosed. The analogs comprise a phosphoamidate or ester bond that is hydrolyzed in vivo to yield a corresponding phosphonate nucleotide analog. Methods and intermediates for their synthesis and use are described.

The invention is about the measuring method of Inorganic Phosphates and its diagnosis reagent box. Producing hydroperoxide by reacting pyruvate oxidase with pyruvate under the activation ofInorganic Phosphates in the sample of plasma or serum and so on, and producing acetaldehydeby reacting hydroperoxide with alcohol under the existence of hydroperoxide enzyme, and then transferring oxidized coenzyme to reduced coenzyme by reacting acetaldehyde and aldehyde dehydrogenase, testing the ascending range of dominant wave-length34nm absorbance before and after the reaction and finally measuring the content of Inorganic Phosphates. This method has high specificity and would not be contaminated by material of internal and exogenous sources, and the result is precise and accurate. Diving the diagnosis reagent box into double-dose or three-dose can reduces the cross interaction of each element, keeps the stability of the reagent and deposits chronically. Using this method can realize the fast testing in common ultraviolet/ visible light analyzer or semiautomatic/automatic analyzer and doesní»t require special or additional apparatus, so the cost is low. Thus, this method can be easily promoted and applied in the whole industry.

Disclosed are compounds for SH2 domain binding inhibition. For example, disclosed is a compound of formula (I)

wherein R₁ is a lipophile; R₂, in combination with the phenyl ring, forms a phenylphosphate mimic group or a protected phenylphosphate mimic group; R₃ is hydrogen, azido, amino, carboxyalkyl, alkoxycarbonylalkyl, aminocarbonylalkyl, or alkylcarbonylamino, wherein the alkyl portion of R₃ may be optionally substituted with a substituent selected from the group consisting of halo, hydroxy, carboxyl, amino, aminoalkyl, alkyl, alkoxy, and keto; R₆ is a linker; AA is an amino acid; and n is 1 to 6; or a salt thereof. Also disclosed are a pharmaceutical composition, a method for inhibiting an SH2 domain from binding with a phosphoprotein and a method of treating breast cancer.

Disclosed herein are phenylalanine derivative compounds of the following formula

W—Y—(AA)_n—Z

wherein Y is a phenylalanyl radical, AA is an amino acid, n is an integer of 1 to 15, and substituent variables W and Z are as described herein. The compounds can be used to inhibit SH2 binding with phosphoproteins, and to inhibit proliferation of tumor cells.

The invention provides a phosphate solubilizing gene psa A. The nucleotide sequence of the phosphate solubilizing gene psa A is as shown in SEQ ID No.1. The nucleotide sequence of a protein coded by the phosphate solubilizing gene psa A is as shown in SEQ ID No.2. The phosphate solubilizing gene psa A cloned through heterologous expression can be used for efficiently generating acetic acids, has a function of converting indissoluble phosphate into effective phosphate and provides a base material for increasing the utilization rate of a phosphate fertilizer by using a molecular biology means.

The invention discloses application of acid phosphatase and related biological materials thereof in constructing phosphate-solubilizing engineering bacteria. The application refers to application of protein as shown in a) or b) or c) or d) in phosphohydrolase: a) protein constituted by amino acid sequences on 1st-203rd sites of SEQ ID N0.2; b) protein constituted by amino acid sequences on 26th-203rd sites of SEQ ID N0.2; c) fusion protein obtained by fusing a protein tag/protein tags on carboxyl terminal (C terminal) or/and amino terminal (N terminal) of the protein of a) or b); and d) protein which is obtained by substituting and/or deleting and/or adding one or more amino acid residues of an amino acid sequence as shown in SEQ ID No.2 or SEQ ID No.6 and has the activity of the acid phosphatase. According to the application disclosed by the invention, biological engineering bacteria, which can effectively activate soil phosphorus nutrients, can be cultivated.

The invention is about the measuring method of inorganic Phosphates and its diagnosis reagent box. Producing hydroperoxide by reacting pyruvate oxidase with pyruvate under the existence of Inorganic Phosphates , then causing enzyme-coupled reaction with peroxidase and oxidating the colorless reduced chromogen combination to quinoneimine chromogen or indamide chromogen dyer with color, testing the variation of dominant wave-length 400ú¡600nm absorbance during the reaction and finally measuring the content of Inorganic Phosphates . This method has high specificity and would not be contaminated by material of internal and exogenous sources, and the result is precise and accurate. Diving the diagnosis reagent box into double-dose or three-dose can reduces the cross interaction of each element, keeps the stability of the reagent and deposits chronically. Using this method can realize the fast testing in common ultraviolet/ visible light analyzer or semiautomatic/automatic analyzer and doesní»t require special or additional apparatus, so the cost is low. Thus, this method can be easily promoted and applied in the whole industry.

The invention is about the measuring method of Inorganic Phosphates and its diagnosis reagent box. Producing hypoxanthine by reacting nucleoside phosphorylase with carnine under the existence of Inorganic Phosphates in the sample of plasma, serum and so on, then producing urate and hydroperoxide by reactinghypoxanthine withxanthine oxidase, and then reacting bimolecular hydroperoxide with peroxidaseand oxidating the colorless reduced chromogen combination to quinoneimine chromogen or indamide chromogen dyer with color, testing the variation of dominant wave-length400ú¡600nmabsorbance during the reaction and finally measuring the content of Inorganic Phosphates . This method has high specificity and would not be contaminated by material of internal and exogenous sources, and the result is precise and accurate. Using this method can realize the fast testing in common ultraviolet/ visible light analyzer or semiautomatic/automatic analyzer and doesní»t require special or additional apparatus, so the cost is low. Thus, this method can be easily promoted and applied in the whole industry.